References in periodicals archive ?
CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetyic and molecular study of 24 cases.
Apart from HCL, expression of CD103 is seen in HCL variant, a subset of splenic marginal zone lymphomas and rare cases morphologically classified as splenic red pulp lymphoma with villous lymphocytes, prolymphocytic leukemia, and diffuse large B-cell lymphoma.
Dilution of neoplastic cells by normal hematolymphoid cells is another factor that may lower the sensitivity of flow cytometry (eg, in acute leukemias with a "dry-tap" bone marrow aspirate specimen, marginal zone lymphomas with residual benign lymphoid follicles, and some cases of angioimmunoblastic T-cell lymphoma).
We continue to explore the use of ibrutinib in non-Hodgkin's lymphoma, including marginal zone lymphoma and its three sub-types, given its unique mechanism of action and ability to target the B-cell receptor pathway," said Darrin Beaupre, M.
Dr Matt Kaiser, Head of Research at Leukaemia & Lymphoma Research, said: Understanding how different genetic changes contribute to a patients disease has allowed us to make huge strides in designing treatments for many different blood cancers, but until now splenic marginal zone lymphoma has been a bit behind.
Splenic marginal zone lymphoma, including splenic lymphoma with villous lymphocytes
Because of similar clinical presentation, morphology, and immunophenotype, HSTL must be distinguished from the following lymphoid neoplasms: aggressive NK-cell leukemia, T-cell large granular lymphocytic leukemia (T-LGL), T-lymphoblastic leukemia (T-LBL), other peripheral T-cell lymphomas, splenic marginal zone lymphoma, and hairy cell leukemia.
17 August 2011 - US-based biopharmaceutical company Emergent BioSolutions Inc (NYSE:EBS) today announced the initiation of a Phase Ib/II study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin's B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma.
Seventeen of these patients had follicular lymphoma, 10 had small lymphocytic lymphoma, 5 had mantle cell lymphoma, 2 had marginal zone lymphoma and 4 had diffuse large B-cell lymphoma.
IGHVgene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas.
Cutaneous marginal zone lymphoma (42,43) is a low-grade B-cell lymphoma composed of nodular or diffuse proliferation of small to medium-sized cells.
Further, the responses have been observed in patients with different disease etiologies including CLL, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma, suggesting that CAL-101 has the potential to benefit broad numbers of patients with hematologic malignancies.